(NASDAQ: CTNM) Contineum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.
Contineum Therapeutics's earnings in 2025 is -$49,831,000.On average, 3 Wall Street analysts forecast CTNM's earnings for 2025 to be -$60,624,801, with the lowest CTNM earnings forecast at -$74,251,346, and the highest CTNM earnings forecast at -$47,603,650. On average, 3 Wall Street analysts forecast CTNM's earnings for 2026 to be -$63,299,919, with the lowest CTNM earnings forecast at -$73,475,199, and the highest CTNM earnings forecast at -$45,275,211.
In 2027, CTNM is forecast to generate -$43,981,633 in earnings, with the lowest earnings forecast at -$77,873,362 and the highest earnings forecast at -$10,089,904.